drugset / Trial / NCT03287375

Treatment of Peritoneal Carcinomatosis With Pressurized IntraPeritoneal Aerosol Chemotherapy -

NCT03287375 ↗

Phase 2 Completed 143 enrolled Michael Bau Mortensen
NaSingle-groupOpen-labelTreatment

Summary

This is a study, where the efficacy of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) against peritoneal metastases will be evaluated. Furthermore, this study will focus on the best evaluation method, where both Quality of Life questionnaires, repeated histology, cytology and MRI will be used.

Timeline

Start
2016-12-01
Primary completion
2022-02-01
Completion
2022-10-01

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

paper The primary outcome of PIPAC-OPC2 is to evaluate if PIPAC can induce major or complete response (PRGS 1 or 2) within a series of three PIPAC procedures. PMID 30911656 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 7.5 mg/m2 Other
Subject Doxorubicin Other / unclassified 1.5 mg/m2 Other
Subject Oxaliplatin Small molecule 92 mg/m2 Other